BLU-945 |
Catalog No.GC63910 |
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2660250-10-0
Sample solution is provided at 25 µL, 10mM.
receptor (EGFR). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112)[1].
[1]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *